O. Wainberg
National Technological University
207 Papers
1.1K Citations
O. Wainberg is an academic researcher from National Technological University. The author has contributed to research in topics: Pierre Auger Observatory & Cosmic ray. The author has an hindex of 50, co-authored 99 publications. Previous affiliations of O. Wainberg include National Atomic Energy Commission & National University of General San Martín.
Chat about Author
Papers
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
Samuel J. Klempner,Bassam Bassam Sonbol,O. Wainberg,Hope E. Uronis,Vi K. Chiu,Aaron Scott,Syma Iqbal,Mohamedtaki Abdulaziz Tejani,Melissa C Stilian,Mathis Thoma,Michael H. Kagey,Jason Baum,Cynthia A. Sirard,Rachel A. Altura,Jaffer A. Ajani +14 more
TL;DR: In this paper , the authors presented 2-year survival data for 1L advanced GEA patients who received combination treatment with DKN-01, the Fc-optimized anti-PD-1 tislelizumab, and CAPOX chemotherapy.
7
Analog multiplexer for testing multianode photomultipliers used in AMIGA project of the Pierre Auger Observatory
A. Lucero,A. Lucero,Alejandro Almela,Alejandro Almela,Federico Suarez,Federico Suarez,C. Reyes,Angel Cancio,A. Fuster,A. Fuster,F. Gallo,F. Gallo,M. R. Hampel,M. R. Hampel,M. Platino,M. Videla,O. Wainberg,O. Wainberg,D. Yelos,A. Etchegoyen,A. Etchegoyen +20 more
TL;DR: Lucero, Agustin, et al. as mentioned in this paper presented a study of the relationship between the Nacional de Investigaciones Cientificas and Tecnicas.
7
Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study.
Yelena Y. Janjigian,Salah-Eddin Al-Batran,O. Wainberg,Eric van Cutsem,Daniela Molena,K. Muro,W. J. Hyung,Lucjan Wyrwicz,Do-Youn Oh,Takeshi Omori,Markus H. Moehler,Marcelo Garrido,Sulene CS Oliveira,Moishe Liberman,V. Castro Oliden,M. Bilici,J. Kurland,I. Xynos,H. Mann,Josep Tabernero +19 more
TL;DR: Subgroup analysis of pCR rates with FLOT and D + FLOT in GC/GEJC by region and country from the MATTERHORN study showed consistent improvement with D + FLOT across all regions.
7
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
John G. Strickler,Antonio Cubillo,Jingmei Liang,Marc R. Matrana,Mark Kozloff,Thomas Lowe,Martha Blaney,Mohammad Sahtout,Louie Naumovski,O. Wainberg +9 more
TL;DR: Treatment with dilpacimab + FOLFIRI was not well tolerated and did not provide clinical benefit to patients with mCRC compared with bevacizumab + F OLFIRI.
7
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy,Yan Chen,Peter Countryman,Bartosz Chmielowski,Stephen P. Anthony,John H. Healey,O. Wainberg,Allen Lee Cohn,B. Shapiro,Vicki L. Keedy,Arun D. Singh,Igor Puzanov,Andrew J. Wagner,M. Qian,Michael N. Sterba,Henry H. Hsu,Sandra Tong-Starksen,William D. Tap +17 more
TL;DR: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT.
6